ADMA BIOLOGICS, INC.
ADMA · XNASCIK 1368514fmd_148323BEA7QNPX1YZ0MWFCP9P9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2006 to Sep 30, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 11 | 23 | 17 | 29 | 42 | 81 | 154 | 258 | 426 | 510 |
| Cost of revenue | 2 | 29 | 42 | 40 | 61 | 80 | 119 | 169 | 207 | 217 |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Gross profit | 4 | (6) | (25) | (10) | (19) | 1 | 35 | 89 | 220 | 293 |
| Research and development | 8 | 6 | 4 | 2 | 6 | 4 | 4 | 3 | 2 | 5 |
| Selling, general and administrative | – | – | – | – | 35 | 43 | 52 | 59 | 74 | 92 |
| Total operating expenses | 28 | 62 | 77 | 71 | 46 | 60 | 75 | 67 | 81 | 101 |
| Operating income | (17) | (39) | (60) | (41) | (65) | (58) | (39) | 22 | 139 | 191 |
| Interest expense | 2 | 3 | 6 | 9 | 12 | 13 | 19 | 25 | 14 | 7 |
| Interest and investment income | – | – | – | 1 | 0 | 0 | 0 | 2 | 2 | 2 |
| Other non-operating income (expense) | (2) | (4) | (5) | (7) | (11) | (13) | (27) | (50) | (13) | (9) |
| Income before taxes | (20) | – | – | – | – | – | (66) | (28) | 126 | 183 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (72) | 36 |
| Net income from continuing operations | (20) | – | – | – | – | – | (66) | (28) | 198 | 147 |
| Net income | (20) | (44) | (66) | (48) | (76) | (72) | (66) | (28) | 198 | 147 |